- Home
- ROIV vs TOL Comparison
ROIV vs TOL Comparison
Compare ROIV & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- TOL
- Stock Information
- Founded
- ROIV 2014
- TOL 1967
- Country
- ROIV United Kingdom
- TOL United States
- Employees
- ROIV N/A
- TOL N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- TOL Homebuilding
- Sector
- ROIV Health Care
- TOL Consumer Discretionary
- Exchange
- ROIV Nasdaq
- TOL Nasdaq
- Market Cap
- ROIV 8.4B
- TOL 9.8B
- IPO Year
- ROIV N/A
- TOL N/A
- Fundamental
- Price
- ROIV $10.95
- TOL $103.26
- Analyst Decision
- ROIV Buy
- TOL Buy
- Analyst Count
- ROIV 4
- TOL 16
- Target Price
- ROIV $17.50
- TOL $142.33
- AVG Volume (30 Days)
- ROIV 6.2M
- TOL 1.4M
- Earning Date
- ROIV 05-29-2025
- TOL 05-20-2025
- Dividend Yield
- ROIV N/A
- TOL 0.96%
- EPS Growth
- ROIV N/A
- TOL 12.43
- EPS
- ROIV N/A
- TOL 14.58
- Revenue
- ROIV $122,585,000.00
- TOL $10,758,023,000.00
- Revenue This Year
- ROIV N/A
- TOL $0.01
- Revenue Next Year
- ROIV N/A
- TOL $3.42
- P/E Ratio
- ROIV N/A
- TOL $7.12
- Revenue Growth
- ROIV 140.04
- TOL 5.86
- 52 Week Low
- ROIV $8.73
- TOL $86.67
- 52 Week High
- ROIV $13.06
- TOL $169.52
- Technical
- Relative Strength Index (RSI)
- ROIV 55.44
- TOL 54.93
- Support Level
- ROIV $10.90
- TOL $101.49
- Resistance Level
- ROIV $11.77
- TOL $104.44
- Average True Range (ATR)
- ROIV 0.30
- TOL 2.66
- MACD
- ROIV 0.01
- TOL 0.99
- Stochastic Oscillator
- ROIV 56.60
- TOL 84.14
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.